Biocon Ltd (BIOCON)
·Next Day Close·-1.57%·₹375
Key EventBiocon's Malaysian unit receives MHRA approval for insulin fill-finish facility
Biocon Ltd (BIOCON)
·Next Day Close·-1.46%·₹389.25
Key EventBiocon's Pertuzumab biosimilar secures EMA CHMP approval recommendation
Biocon Ltd (BIOCON)
·Next Day Close·-1.27%·₹390
Key EventFinal dividend of ₹0.50 per share approved for FY 2025-26
ImpactShareholders receive ₹0.50 per share as final dividend after AGM approval.Sign up to read impact
Biocon Ltd (BIOCON)
·Next Day Close·+0.62%·₹395
Key EventBiocon secures 10-year supply contract for Pertuzumab in Brazil
ImpactThis partnership provides Biocon with long-term revenue potential and market entry in Brazil's public healthcare system.Sign up to read impact
Biocon Ltd (BIOCON)
·Next Day Close·+0.62%·₹395
Key EventBiocon schedules analyst/investor meetings for September 11
ImpactInvestors should monitor Biocon's upcoming meetings for potential market-moving updates and strategic insights.Sign up to read impact
Biocon Ltd (BIOCON)
·Next Day Close·-0.93%·₹401.25
Key EventBiocon schedules analyst meetings for September 4, 2026
ImpactInvestors should monitor these meetings for potential market-moving updates on company strategy or performance.Sign up to read impact
Biocon Ltd (BIOCON)
·Next Day Close·-1.56%·₹405
Key EventFinal dividend of ₹0.50 per share approved for FY 2025-26
Biocon Limited (BIOCON)
·Next Day Close·+0.68%·₹417.4
Key EventBiocon's biosimilar receives Japan MHLW marketing approval
Biocon Limited (BIOCON)
·Next Day Close·-0.89%·₹414.3
Key EventBiocon's U.S. subsidiary secures FDA approval for Yesintek® autoinjectors
Biocon Limited (BIOCON)
·Next Day Close·-0.3%·₹428.7
Key EventManagement to meet analysts at Motilal Oswal investor conference
ImpactInvestors should monitor the meeting for potential updates on company strategy or performance.Sign up to read impact